CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Management of adult patients with haematological malignancies in critical care.
Management of adult patients with haematological malignancies in critical care.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
血液系统恶性肿瘤种类繁多,临床表现和预后各不相同。血液系统恶性肿瘤患者可能在诊断时或因治疗相关效应和并发症而需要入住重症监护室。尽管此类需要重症监护的患者的预后已有所改善,但最佳临床管理仍存在不确定性。识别哪些患者能从重症监护入住中获益具有挑战性,而选择性引入姑息治疗可能有助于减少不必要和无益的治疗。虽然血液系统恶性肿瘤患者对重症监护医生而言可能构成挑战,但仍可取得良好的结局。在这篇叙述性综述中,我们为重症监护医生简要概述了相关的血液系统恶性肿瘤以及近期治疗进展的总结。随后,我们重点讨论血液系统恶性肿瘤患者的重症监护管理,包括脓毒症;急性呼吸衰竭;肿瘤溶解综合征的预防和治疗;血小板减少症;以及静脉血栓栓塞症。
我们还讨论了免疫治疗特异性相关并发症及其管理,包括与CAR-T 细胞治疗相关的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。虽然血液系统恶性肿瘤的管理高度专业化且日益集中化,但急性病情恶化的患者往往就诊于当地医院,其并发症需要重症监护专业知识。本综述旨在为非专科重症监护团队提供关于疾病和管理原则的当代概述。
There are a diverse range of haematological malignancies with varying clinical presentations and prognoses. Patients with haematological malignancy may require admission to critical care at the time of diagnosis or due to treatment related effects and complications. Although the prognosis for such patients requiring critical care has improved, there remain uncertainties in optimal clinical management. Identification of patients who will benefit from critical care admission is challenging and selective involvement of palliative care may help to reduce unnecessary and non-beneficial treatments.
While patients with haematological malignancy can present a challenge to critical care physicians, good outcomes can be achieved. In this narrative review, we provide a brief overview of relevant haematological malignancies for the critical care physician and a summary of recent treatment advances. Subsequently, we focus on critical care management for the patient with haematological malignancy including sepsis; acute respiratory failure; prevention and treatment of tumour lysis syndrome; thrombocytopaenia; and venous thromboembolism.
We also discuss immunotherapeutic-specific related complications and their management, including cytokine release syndrome and immune effector cell associated neurotoxicity syndrome associated with chimeric antigen receptor T-cell therapy.
While the management of haematological malignancies is highly specialised and increasingly centralised, acutely unwell patients often present to their local hospital with complications requiring critical care expertise. The aim of this review is to provide a contemporary overview of disease and management principles for non-specialist critical care teams.
MEMBER ACCOUNT
登录成功会直接打开下一页。